Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action

被引:25
作者
Anzueto, Antonio [1 ]
Miravitlles, Marc [2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, Pulm Crit Care, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA
[2] Hosp Univ Vall dHebron, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Pneumol Dept, Barcelona, Spain
关键词
COPD; Exacerbations; Primary care; INHALER ADHERENCE; AIR-POLLUTION; COPD; THERAPY; TRIAL; REHABILITATION; SALMETEROL; MEDICATION; MANAGEMENT; INFECTION;
D O I
10.1016/j.amjmed.2018.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, with exacerbations contributing strongly to the overall severity and burden of disease at the individual level. Many patients with COPD are managed predominantly in the primary care setting; therefore, primary care physicians (PCPs) must be aware of and understand the causes, effects, and management of COPD exacerbations. This review offers practical information about how exacerbations are defined in the treatment setting, pathogenic and environmental causes, options for exacerbation treatment and prevention, and suggestions for improving care in the clinic. Exacerbations have a strong negative effect on patients and are associated with an increased risk of further exacerbations and decreases in lung function. Thus, it is important that exacerbations not requiring hospitalization be identified and confidently managed in the clinical setting. Understanding treatment options for acute exacerbations and maintenance treatment to prevent future exacerbations may help PCPs better understand what they can do to support their patients. This review aims to provide useful guidance for PCPs to identify exacerbations and adjust their practice for optimal management of exacerbations in patients with COPD. It also aims to encourage PCPs that they have an important task in integrating effective COPD management into the primary care setting. (C) 2018 Published by Elsevier Inc.
引用
收藏
页码:S15 / S22
页数:8
相关论文
共 90 条
[1]   Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? [J].
Al-Showair, Raid A. M. ;
Tarsin, Walid Y. ;
Assi, Khaled H. ;
Pearson, Stantey B. ;
Chrystyn, Henry .
RESPIRATORY MEDICINE, 2007, 101 (11) :2395-2401
[2]   Seasonality, ambient temperatures and hospitalizations for acute exacerbation of COPD: a population-based study in a metropolitan area [J].
Almagro, Pere ;
Hernandez, Carme ;
Martinez-Cambor, Pable ;
Tresserras, Ricard ;
Escarrabill, Joan .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 :899-908
[3]   The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis [J].
Alwashmi, Meshari ;
Hawboldt, John ;
Davis, Erin ;
Marra, Carlo ;
Gamble, John-Michael ;
Abu Ashour, Waseem .
JMIR MHEALTH AND UHEALTH, 2016, 4 (03)
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]   The asthma - chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges [J].
Barrecheguren, Miriam ;
Esquinas, Cristina ;
Miravitlles, Marc .
CURRENT OPINION IN PULMONARY MEDICINE, 2015, 21 (01) :74-79
[6]   Hospital Readmissions for COPD: We Can Meet the Challenge [J].
Braman, Sidney S. .
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2015, 2 (01) :4-7
[7]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[8]  
Calverley PMA, 2017, AM J RESP CRIT CARE, V195, P1125, DOI [10.1164/rccm.201703-0560ED, 10.1164/rccm.201612-2525LE]
[9]   Inhaled β2-adrenoceptor agonists cardiovascular safety in patients with obstructive lung disease [J].
Cazzola, M ;
Matera, MG ;
Donner, CF .
DRUGS, 2005, 65 (12) :1595-1610
[10]   β2-Agonist Therapy in Lung Disease [J].
Cazzola, Mario ;
Page, Clive P. ;
Rogliani, Paola ;
Matera, M. Gabriella .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (07) :690-696